LGVN Longeveron (LGVN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001721484
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
20
13F, latest reported quarter
Longeveron insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Longeveron Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (5 buys, 5 sales), the last on May 29, 2025.
- +166.1% median (+132.5% mean) 90-day return after 5 previous buys.
- The trade is 5.3% of the 209,034 shares held after it.
- 1 other insider sold within 30 days.
- 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Soffer Rock sold about $13.8K of LGVN on May 30, 2025, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (5 buys, 4 sales), the last on May 22, 2025.
- +166.1% median (+132.5% mean) 90-day return after 5 previous buys.
- The trade is 4.5% of the 220,034 shares held after it.
- 1 other insider sold within 30 days.
- 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Soffer Rock sold about $13.0K of LGVN on May 29, 2025, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (5 buys, 3 sales), the last on Apr 11, 2024.
- +166.1% median (+132.5% mean) 90-day return after 5 previous buys.
- The trade is 0.9% of the 230,034 shares held after it.
- 1 other insider sold within 30 days.
- 20 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Soffer Rock sold about $2.6K of LGVN on May 22, 2025; 1 other insider sold within 30 days and 20 funds added in the latest 13F quarter.37 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
20 funds bought in last quarter
below 68% of Pharma & Biotech
Revenue
-49.9% year over year
below 80% of Pharma & Biotech
Margin
-1893.6% net margin
below 91% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LGVN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+88.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LGVN: institutional holders (13F)
13F holdings, latest reported quarter
1,353,881 sh
$951.8K
1,287,000 sh
$904.8K
581,305 sh
$408.7K
224,170 sh
$157.6K
203,761 sh
$143.2K
Congress trades in LGVN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LGVN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LGVN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$89.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$127.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$15.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$18.5K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$254.0K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$2.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
3
Phase 2
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 20 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LGVN financials
Revenue growth
-49.9%
XBRL, annual
Net margin
-1893.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LGVN
| FY Dec 2025 | $1.2M |
| FY Dec 2024 | $2.4M |
| FY Dec 2023 | $709.0K |
| FY Dec 2022 | $1.2M |
| FY Dec 2021 | $1.3M |
| Jun 2026 | $287.0K |
| Mar 2026 | $398.0K |
| Dec 2025 | $365.0K |
| Sep 2025 | $137.0K |
| Jun 2025 | $316.0K |
| Mar 2025 | $381.0K |
| Dec 2024 | $603.0K |
| Sep 2024 | $773.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-1,978%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LGVN
| FY Dec 2025 | -1,894% |
| FY Dec 2024 | -667.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1,541% |
| FY Dec 2021 | -1,305% |
| Jun 2026 | -2,116% |
| Mar 2026 | -1,190% |
| Dec 2025 | -1,492% |
| Sep 2025 | n/a |
| Jun 2025 | -1,591% |
| Mar 2025 | -1,315% |
| Dec 2024 | -676.8% |
| Sep 2024 | -571.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$20.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LGVN
| FY Dec 2025 | -$18.9M |
| FY Dec 2024 | -$14.5M |
| FY Dec 2023 | -$19.3M |
| FY Dec 2022 | -$14.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$5.8M |
| Mar 2026 | -$4.4M |
| Dec 2025 | -$5.3M |
| Sep 2025 | -$5.1M |
| Jun 2025 | -$3.8M |
| Mar 2025 | -$4.7M |
| Dec 2024 | -$3.4M |
| Sep 2024 | -$3.3M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term 2021-09-30 (57 months older than the period end) plus current 2021-09-30 (57 months older than the period end); equity 2026-06-30
Debt to equity LGVN
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.01x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-137.66x
TTM operating cash flow over long-term 2021-09-30 (57 months older than the period end) plus current 2021-09-30 (57 months older than the period end)
Cash flow to debt LGVN
| FY Dec 2025 | -125.98x |
| FY Dec 2024 | -93.70x |
| FY Dec 2023 | -128.39x |
| FY Dec 2022 | -94.39x |
| FY Dec 2021 | -65.11x |
| Jun 2026 | -137.66x |
| Mar 2026 | -123.77x |
| Dec 2025 | -125.98x |
| Sep 2025 | -112.99x |
| Jun 2025 | -98.04x |
| Mar 2025 | -104.59x |
| Dec 2024 | -93.70x |
| Sep 2024 | -97.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-203.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LGVN
| FY Dec 2025 | -164.7% |
| FY Dec 2024 | -111.6% |
| FY Dec 2023 | -157.2% |
| FY Dec 2022 | -65.0% |
| FY Dec 2021 | -86.5% |
| Jun 2026 | -203.6% |
| Mar 2026 | -135.2% |
| Dec 2025 | -164.7% |
| Sep 2025 | -119.9% |
| Jun 2025 | -134.5% |
| Mar 2025 | -167.6% |
| Dec 2024 | -111.6% |
| Sep 2024 | -111.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-145.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LGVN
| FY Dec 2025 | -126.8% |
| FY Dec 2024 | -84.9% |
| FY Dec 2023 | -108.4% |
| FY Dec 2022 | -53.7% |
| FY Dec 2021 | -65.6% |
| Jun 2026 | -145.6% |
| Mar 2026 | -106.7% |
| Dec 2025 | -126.8% |
| Sep 2025 | -93.9% |
| Jun 2025 | -102.6% |
| Mar 2025 | -110.8% |
| Dec 2024 | -84.9% |
| Sep 2024 | -86.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LGVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-192.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LGVN
| FY Dec 2025 | -159.8% |
| FY Dec 2024 | -106.0% |
| FY Dec 2023 | -136.8% |
| FY Dec 2022 | -57.6% |
| FY Dec 2021 | -76.8% |
| Jun 2026 | -192.0% |
| Mar 2026 | -130.8% |
| Dec 2025 | -159.8% |
| Sep 2025 | -118.5% |
| Jun 2025 | -131.6% |
| Mar 2025 | -156.4% |
| Dec 2024 | -106.0% |
| Sep 2024 | -100.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LGVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value LGVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield LGVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LGVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $709.0K | $1.2M |
| Gross profit | $803.0K | $1.9M | $221.0K | $497.0K |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M |
| EPS (diluted) | n/a | n/a | n/a | -0.90 |
| Operating cash flow | -$18.6M | -$13.9M | -$19.0M | -$14.0M |
| Cash | $4.7M | $19.2M | $4.9M | $10.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
LGVN Stock Sonar score 5/7 axes
Find similar shapesCompareLGVN ranks highest on financial health (40th percentile) and risk and compliance (37th), and lowest on profitability (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
